Surveillance May Reduce CIN 2 Overtreatment - Top-Institutions - MDSpire

Surveillance May Reduce CIN 2 Overtreatment

Risk-based management may reduce unnecessary excisions in selected patients with CIN 2.

  • By

  • Andrea Surnit

  • June 26, 2026

  • 3 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Kaiser Permanente Northern California
    Kaiser Permanente Northern California

    Oakland, California

    Key Differentiators

    • Gynecology

  • #2

    National Cancer Institute
    National Cancer Institute

    Bethesda, Maryland

    Key Differentiators

    • Cancer Research

  • #3

    Winthrop University Hospital
    Winthrop University Hospital

    Mineola, New York

    Key Differentiators

    • Gynecology

  • #4

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Gynecology
    • Oncology

  • #5

    University of California Comprehensive Cancer Center, San Francisco
    University of California Comprehensive Cancer Center, San Francisco

    San Francisco, California

    Key Differentiators

    • Cancer Research

Original Source(s)

Surveillance May Reduce CIN 2 Overtreatment

  • by Andrea Surnit

  • June 26, 2026

Related Content

Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database

Study Reassures on Safety of Early NSAID Use

A large cohort found no adjusted link to major congenital malformations, but questions remain for miscarriage, later pregnancy, and other outcomes.

Pregnancy Risks With First Trimester GLP-1 Continuation

Claims-based target trial emulation found no clear association between continued GLP-1 receptor agonist use in early pregnancy and nonlive birth, fetal growth abnormalities, or major congenital malformations.